Trial Profile
A Multi-country, Prospective, Clinical Safety Study of Subjects Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Ad26 EBOV vaccine (Primary) ; Modified Vaccinia Ankara Bavarian Nordic Ebola Marburg vaccine (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions; Registrational
- Sponsors Janssen Vaccines and Prevention B.V
- 12 Dec 2023 Status changed from completed to discontinued.
- 15 Feb 2022 Status changed from active, no longer recruiting to completed.
- 16 Dec 2021 This trial has been completed in France, according to European Clinical Trials Database record.